Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tomudex

(Raltitrexed)

Phase 3Small molecule

NNanjing Chia-tai Tianqing Pharmaceutical

Raltitrexed is used to treat certain types of cancer, particularly colorectal cancer. It works by stopping cancer cells from growing and dividing.[1] Tomudex is currently being investigated across 18 indications[3], with its most advanced program in Phase 3.[1]

Tomudex is one of 429 small molecule programs targeting Childhood Acute Lymphoblastic Leukemia. It is currently in Phase 3.

18

Indications

32

Total Trials

3

Active Trials

428

Competitors

Pipeline

Status by Indication[3][1]

Indication

Childhood Acute Lymphoblastic LeukemiaActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Esophageal CancerActive, not recruiting

MesotheliomaActive, not recruiting

Colorectal NeoplasmActive, not recruiting

Malignant MesotheliomaActive, not recruiting

Bile Duct AdenomaActive, not recruiting

Rectal AdenocarcinomaUnknown

Childhood Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

MesotheliomaPhase 3

Active, not recruiting

Colorectal NeoplasmPhase 1

Active, not recruiting

Malignant MesotheliomaPhase 2

Active, not recruiting

Bile Duct AdenomaPhase 2

Active, not recruiting

Rectal AdenocarcinomaPreclinical

Unknown

Showing 10 of 18 indications

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Tomudex

NNanjing Chia-tai Tianqing Pharmaceutical

Gemzar

GGynecologic Oncology Group

Medrol

ABI-007

Bristol-Myers Squibb

Chemotherapy Agents

Meglitinides

LDE225

Alpha-Glucosidase Inhibitors

Thiazolidinediones

Sulfonylureas

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Treatment

NCT06652412

Clinical

Trials by Indication[1]

Colorectal Cancer11 trials

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Unknown status·FFudan University·Phase 2·NCT03823079·50 enrolled

Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer

Unknown status·FFudan University·Phase 2·NCT02618356·82 enrolled

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 2·NCT03126071·100 enrolled

Show 8 more trials

Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·—·Phase 2·NCT03053167·100 enrolled

Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases

Unknown status·NNanjing Chia-tai Tianqing Pharmaceutical·Phase 4·NCT01959061·320 enrolled

Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·FFudan University·Phase 2·NCT02376452·100 enrolled

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·—·Phase 1/2·NCT05426811·50 enrolled

Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Unknown status·MMedical Research Council·Phase 3·NCT00002893·900 enrolled

Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure

Completed·CCentre Georges Francois Leclerc·Phase 2·NCT01348412·31 enrolled

Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00002828

A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 2·NCT04241731·50 enrolled

Malignant Mesothelioma2 trials

Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00004920·256 enrolled

Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00004254·25 enrolled

Fruquintinib1 trial

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

Recruiting·MMeng Qiu·Phase 2·NCT06427005·66 enrolled

Pancreatic Cancer1 trial

The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT04581876·120 enrolled

Refractory Solid Tumors1 trial

Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors

Completed·FFox Chase Cancer Center·Phase 1·NCT00003109·39 enrolled

16 more indications

Metastatic Colorectal Cancer1 trial

SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05160896·90 enrolled

Gastric Cancer1 trial

Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection

Unknown status·ZZhongnan Hospital·Phase 2·NCT03392103·48 enrolled

Esophageal Cancer1 trial

A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer

Unknown status·TThe First People's Hospital of Lianyungang·Phase 2·NCT01732380·108 enrolled

Head and Neck Squamous Cell Cancer1 trial

Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 3·NCT02485548·120 enrolled

Older Patients1 trial

Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC.

Unknown status·TThe First Affiliated Hospital of Dalian Medical University·Phase 4·NCT03196843·202 enrolled

First-line Treatment1 trial

RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)

Unknown status·SShenzhen People's Hospital·Phase 2·NCT03813641·100 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT03083613·41 enrolled

Treatment1 trial

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

Not yet recruiting·FFudan University·Phase 2·NCT06652412·124 enrolled

Hypofractionated Radiotherapy1 trial

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT05628038·93 enrolled

Liver Metastases1 trial

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Unknown status·FFudan University·Phase 2·NCT05435313·39 enrolled

Patients With Advanced Solid Tumors1 trial

Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00002902

Squamous Cell Carcinoma1 trial

Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus

Unknown status·HHuai'an First People's Hospital·Phase 2·NCT03585530·32 enrolled

Acute Leukemia1 trial

Raltitrexed in Treating Children With Refractory Acute Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003528·30 enrolled

Rectal Cancer1 trial

Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer

Completed·NNational Cancer Institute, Naples·Phase 2·NCT01481545·62 enrolled

Locally-advanced Rectal Cancer1 trial

Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT02992886·68 enrolled

Unspecified1 trial

Raltitrexed in HIPEC

Completed·FFudan University·Phase 1·NCT04761185·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 32 trial records for Raltitrexed. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Raltitrexed compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Raltitrexed. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing Chia-tai Tianqing Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Thymidylate Synthase Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNanjing Chia-tai Tianqing Pharmaceutical

Related News